See the DrugPatentWatch profile for lurbinectedin

After conducting a thorough search using the available information, I was unable to find specific guidelines for administering Lurbinectedin. However, I did find information regarding its approval and usage.

Lurbinectedin is a selective inhibitor of oncogenic transcription. It received its first approval in June 2020 from the European Commission for the treatment of adult patients with metastatic platinum-resistant small cell lung cancer (pRSCLC) who have received at least two prior lines of therapy [1].

In terms of administration, Lurbinectedin is given as a 1-hour intravenous infusion every 21 days until disease progression or unacceptable toxicity [2]. However, it is crucial to consult the official prescribing information or a healthcare professional for detailed administration guidelines, as they are best equipped to provide the most accurate and up-to-date information.

Sources:
[1] DrugPatentWatch.com. (2021). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>
[2] PharmaMar. (2021). Zepzelca (lurbinectedin). Retrieved from <https://www.pharmamar.com/en/profesionales/productos/zepzelca-lurbinectedin/>